Sabine Fürst, Emmanuelle Bernit, Faezeh Legrand, Angela Granata, Samia Harbi, Raynier Devillier, Valerio Maisano, Benjamin Bouchacourt, Thomas Pagliardini, Djamel Mokart, Claude Lemarié, Boris Calmels, Christophe Picard, Agnès Basire, Borje S Andersson, Didier Blaise
Allogeneic stem cell transplantation (Allo-SCT) is the only rapidly available curative treatment modality in patients with severe sickle cell disease (SCD). The development of reduced-toxicity myeloablative conditioning (RT-MAC) regimen and the use of partially matched family donors with post-transplantation cyclophosphamide (PT-Cy) have widened the access to Allo-SCT. Antibodies against donor-specific HLA (DSA) increase the risk of engraftment failure in HLA mismatched Allo-SCT. We report the results of five patients with SCD, whereas three with DSA, who underwent an unmanipulated haploidentical stem cell transplantation (Haplo-SCT) after a busulfan-based RT-MAC regimen with PT-Cy...
March 14, 2024: Bone Marrow Transplantation